On July 26th, 2024, San Francisco in the USA and Suzhou in China / PRNewswire / --With the increase of global aging population and chronic diseases, the demand for new drug development is becoming increasingly urgent. The traditional drug development process is time-consuming and costly. The introduction of AI technology provides a new solution to this difficult problem. Innovent Biologics has been committed to promoting industry development through technological innovation. Recently, Innovent Biologics has partnered with Wecomput to jointly promote the construction and improvement of Innovent Biologics Guoqing Institute's computing platform. Through this cooperation, the two parties will integrate their own advantages resources and technologies, use AI technology to further accelerate the drug development process.
As an important R&D engine of Innovent Biologics, Guoqing Institute has deeply explored and actively deployed in AI drug R&D. In this cooperation, Innovent Biologics Guoqing Institute will use Wecomput's WeMol platform to build and improve the computing platform of Guoqing Institute to accelerate its drug R&D process. Innovent Biologics hopes to reduce the cost of AI landing and experimental costs, shorten the drug R&D cycle, improve the success rate of R&D, and bring more innovative drugs and treatment plans to patients by building an efficient, easy-to-use, digitalized, intelligent, and automated one-stop AI drug development platform.
He Kaijie, Vice President of Tumor Biology and ADC Drug Research at Innovent Biologics Group, said: "AI is injecting new energy into the global pharmaceutical and biotechnology industry. We are very pleased to use the most advanced AI technology to enhance our R&D capabilities and accelerate the discovery and development of innovative drugs. We look forward to making greater breakthroughs in the global pharmaceutical market in the future with strong technical support."
About Wecomput
Wecomput is committed to "computational technology-driven innovative drug R&D". Based on a deep understanding of the innovative drug R&D process, it integrates technologies such as artificial intelligence, biophysics, and high-performance computing to create a unique digital, intelligent, and automated drug molecule generation, design, and simulation platform. It is expected to revolutionize the traditional way of drug discovery and drive the R&D process of innovative drugs such as antibodies, proteins, small molecules, and mRNA. Its parent company, Beijing Zhongda Wecomput Technology Co., Ltd., was registered in 2015, was selected as a national high-tech enterprise, received equity investment from Sequoia Capital in 2021, and was selected as a senior member of the NVIDIA Inception plan. So far, Wecomput has served hundreds of customers at home and abroad, covering many biomedical companies, universities, hospitals, and research institutes, and independently developed leading drug molecule design and intelligent computing platform WeMol.
"Starting with trust and ending with action", developing high-quality biopharmaceuticals that the general public can afford is the ideal and goal of Innovent Biologics. Innovent Biologics was established in 2011 and is committed to the development, production, and sales of innovative drugs to treat major diseases such as tumors, metabolic diseases, and autoimmune diseases. On October 31, 2018, Innovent Biologics went public on the Main Board of the Hong Kong Stock Exchange with stock code: 01801. Since its establishment, the company has stood out among many biopharmaceutical companies with its innovative achievements and international operating model. It has established a product chain including 23 new drug varieties, covering multiple disease areas such as tumors, metabolic diseases, and autoimmune diseases, of which 6 varieties have been selected for the national "Major New Drug Creation" special project, and 3 products (Sintilimab Injection, brand name: Tyvyt, English trademark: TYVYT; Bevacizumab Injection, brand name: Duligotong, English trademark: BYVASDA; Camrelizumab Injection, brand name: Sulinno, English trademark: SULINNO) have been approved.
"Born with trust, delivered through action." Developing high-quality biopharmaceutical products that ordinary people can afford is Innovent Biologics' mission and goal. Established in 2011, Innovent Biologics is committed to the research and development, production, and sales of innovative drugs in major disease areas such as oncology, autoimmunity, metabolism, and ophthalmology, bringing our work to benefit more lives. The company has 10 approved products on the market, including Tyvyt (sintilimab), Halpryza (bevacizumab biosimilar), Optune (tumor treatment fields device), and Pemazyre (pemigatinib). Currently, there are also four varieties under NMPA review, four new drug molecules entering Phase III or key clinical studies, and 18 new drug varieties entering clinical research. The company has reached more than 30 strategic cooperation agreements with international partners such as Eli Lilly, Roche, Sanofi, Adimab, Incyte, and MD Anderson Cancer Center, etc.
While Innovent Biologics is constantly researching and developing innovative drugs and seeking its own development, it adheres to the development concept of economic construction and people-centered. For many years, it has always cherished scientific benevolence, adhered to the concept of "patient-centered," cared for patients and cared about their families, and actively fulfilled social responsibilities. The company has initiated and participated in many charitable drug projects, so that more and more patients can benefit from the progress of life sciences and buy high-quality biopharmaceutical products that are affordable. As of now, Innovent Biologics' patient assistance programs have benefited more than 170,000 ordinary patients, with a total drug donation value of 3.4 billion RMB. Innovent Biologics hopes to work together with everyone to improve the development level of China's biopharmaceutical industry to meet the pursuit of easy access to medication and people's desire for a better life.
For details, please visit the company's website: https://www.innoventbio.com/ or the company's LinkedIn account: Innovent Biologics.
Declaration: Innovent does not recommend the use of unapproved drugs/indications.
Ramucirumab injection (Xiranze) and Sepitinib capsules (Ruituo) are developed by Eli Lilly.